Shilan Mozaffari Selected Research

Irritable Bowel Syndrome (Syndrome, Irritable Bowel)

2/2014	Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients.
12/2012	Benefit of Aloe vera and Matricaria recutita mixture in rat irritable bowel syndrome: Combination of antioxidant and spasmolytic effects.
7/2011	Effects of Hypericum perforatum extract on rat irritable bowel syndrome.
1/2010	Implications of melatonin therapy in irritable bowel syndrome: a systematic review.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shilan Mozaffari Research Topics

Disease

4	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2015 - 03/2009
4	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 02/2014 - 01/2010
3	Constipation 05/2014 - 04/2013
3	Diarrhea 05/2014 - 04/2013
2	Opioid-Induced Constipation 07/2018 - 01/2018
2	Pain (Aches) 01/2018 - 04/2013
2	Crohn Disease (Crohn's Disease) 07/2017 - 05/2014
2	Abdominal Pain (Pain, Abdominal) 03/2015 - 01/2010
1	Chronic Pain 07/2018
1	Neoplasms (Cancer) 01/2018
1	Fistula 07/2017
1	Flatulence 03/2015
1	Colitis 08/2014
1	Ulcerative Colitis 05/2014
1	Progressive Multifocal Leukoencephalopathy 05/2014
1	Hypersensitivity (Allergy) 04/2013
1	Inflammation (Inflammations) 12/2011

Drug/Important Bio-Agent (IBA)

3	MelatoninIBA 04/2013 - 01/2010
2	Opioid Analgesics (Opioids)IBA 07/2018 - 01/2018
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2017 - 07/2011
2	renzaprideIBA 05/2014 - 02/2014
2	ramosetron (Nasea)IBA 05/2014 - 04/2013
2	AntioxidantsIBA 12/2012 - 12/2011
1	methylnaltrexone FDA Link 07/2018
1	Narcotic Antagonists (Opioid Antagonists)IBA 01/2018
1	mu Opioid Receptors (mu Opioid Receptor)IBA 01/2018
1	Adalimumab (Humira)FDA Link 07/2017
1	Certolizumab Pegol FDA Link 07/2017
1	AntibodiesIBA 07/2017
1	Carnitine (L-Carnitine)FDA LinkGeneric 08/2014
1	Butyrates (Butyrate)IBA 08/2014
1	Thiobarbituric Acid Reactive SubstancesIBA 08/2014
1	Biological ProductsIBA 05/2014
1	linaclotideIBA 05/2014
1	Natalizumab (Tysabri)FDA Link 05/2014
1	Serotonin (5 Hydroxytryptamine)IBA 02/2014
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 04/2013
1	mosaprideIBA 04/2013
1	asimadolineIBA 04/2013
1	CRF receptor type 1IBA 04/2013
1	prucaloprideIBA 04/2013
1	pexacerfontIBA 04/2013
1	Pregabalin (Lyrica)FDA Link 04/2013
1	Gabapentin (Neurontin)FDA LinkGeneric 04/2013
1	Glucagon-Like Peptides (Enteroglucagon)IBA 04/2013
1	Parasympatholytics (Antispasmodics)IBA 12/2012
1	Free RadicalsIBA 12/2011
1	Peroxidase (Myeloperoxidase)IBA 07/2011
1	CytokinesIBA 07/2011
1	Lipid PeroxidesIBA 07/2011
1	Plant ExtractsIBA 03/2009

Therapy/Procedure

7	Therapeutics 07/2017 - 03/2009
1	Palliative Care (Palliative Therapy) 07/2018
1	Pain Management 07/2018
1	Analgesia 01/2018